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5 ABSTRACT 
 
6 1. Ebola virus disease (EVD) is a threat to human health and the survival of African great 
 
7 apes.  The  disease  has  led  to  major  population  declines  of  chimpanzees  and  gorillas,  and 
 
8 infected great apes play an important role as sources of human EVD outbreaks. The threat 
 
9 posed by EVD raises the question whether vaccination of wild apes is a possible strategy to 
 
10 reduce the occurence and impact of this disease. 
 
11 2. This article reviews the current knowledge about EVD in great apes and emphasizes the 
 
12 link between ape and human outbreaks. It discusses the need for control strategies such as 
 
13 vaccination and describes aspects of primate behavior, virus biology, vaccine composition, 
 
14 and vaccination principles that are necessary to consider when making management decisions 
 
15 about great ape vaccination. Finally, it identifies gaps in the understanding of Ebola ecology 
 
16 and highlights surveillance and research that can aid the survival of great apes and reduce 
 
17 human exposure to Ebola virus. 
 
18 3.  The  unpredictable  emergence  of  Ebola  viruses  and the  severe  impact  of  EVD  call  for 
 
19 efficient  monitoring  and  ultimately  control  of  Ebola.  This  article  provides  a  platform  for 
 
20 further  interdiciplinary  discussions  to  decide  on  optimal  management  solutions  regarding 
 
21 vaccination of great apes against Ebola. 
 
22 
 
23 KEY WORDS: conservation, Ebola, global health, vaccination, wild great apes 
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27 INTRODUCTION 
 
28 Ebola virus disease (EVD) is an acute, severe and lethal disease of particular concern for 
 
29 humans, chimpanzees, and gorillas (Karesh & Reed 2005, Feldmann & Geisbert 2011). The 
 
30 disease is caused by viruses of the Ebola genus, belonging to the virus family Filoviridae 
 
31 (Kuhn  et  al.  2010).  The  Ebola  genus  comprises  five  distinct  species,  although  they  are 
 
32 generally referred to  as the  Ebola virus or simply Ebola.  Since  the  first Ebola  virus  was 
 
33 discovered  in  1976,  Ebola  viruses  (EVs)  have  sporadically  re-emerged  from  an  unknown 
 
34 reservoir and caused more than 20 human outbreaks across Africa (Anonymous 2015a). The 
 
35 epidemic that started in West Africa in December 2013 has lasted for more than two years and 
 
36 claimed more than 11,000 lives (Anonymous 2015b). 
 
37 EVD is also considered a major threat to the survival of African great apes, all of which are 
 
38 currently listed as Endangered or Critically Endangered (Anonymous 2016a). The disease in 
 
39 apes is also of concern for human health as there is a clear link between Ebola-infected apes 
 
40 and human EVD outbreaks. For all eight human outbreaks in Gabon and the Republic of 
 
41 Congo (ROC) which have occurred in the last 25 years, there is epidemiological evidence 
 
42 (and in three of these outbreaks also laboratory evidence) that they were initiated by contact to 
 
43 infected bush meat from gorillas (Gorilla gorilla gorilla) or chimpanzees (Pan troglodytes 
 
44 troglodytes) (Georges et al. 1999, Rouquet et al. 2005), hence hunting or scavenging of wild 
 
45 great apes is a major risk factor. Bats, monkeys, and perhaps other wildlife are also possibly 
 
46 able  to  infect  humans;  however,  the  true  reservoir(s)  and  natural  circulation  of  EVs  still 
 
47 remain unidentified (Lahm et al. 2007, Leendertz et al. 2015, Maganga et al. 2014, Mari Saez 
 
48 et al. 2015, Olival & Hayman 2014, Olson et al. 2012). This makes prediction, surveillance 
 
49 and control of EVD challenging. 
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50 The threats posed by EVD, raise the question of whether vaccination of wild great apes would 
 
51 be a future option to help mitigate the effect of EVD on ape populations and protect human 
 
52 health.  Although  no  outbreak  has  been  confirmed  in  apes  since  2005,  the  unpredictable 
 
53 pattern  of  virus  emergence  and  the  severe  impact of  outbreaks  mean  that  there  is  a  true 
 
54 concern of future occurrences. 
 
55 This article provides an overview of what is known about EVD in great apes, and highlights 
 
56 surveillance  and  research  that  can  aid  the  survival  of  wild  great  apes  and  reduce  human 
 
57 exposure  to  Ebola  virus.  Moreover,  it  describes  aspects  of  primate  behavior,  Ebola  virus 
 
58 biology and  ecology,  vaccine composition,  and vaccination principles that are essential to 
 
59 know when considering vaccination of great apes. This article provides a platform for further 
 
60 interdiciplinary discussions to decide on optimal management solutions regarding protection 
 
61 of wild great apes against Ebola. 
 
62 
 
63 EBOLA VIRUS DISEASE 
 
64 Four separate species of EVs cause EVD in Africa; Zaire EV (ZEBOV), Sudan EV (SEBOV), 
 
65 Cote d’Ivoire EV (TFEBOV) and Bundibugyo EV (BEBOV), of which ZEBOV and TFEBOV 
 
66 have so far been detected in great apes (Leroy et al. 2004, Rouquet et al. 2005, Wittmann et 
 
67 al. 2007, Kuhn et al. 2010). The genetic diversity of these Ebola species represents a hurdle 
 
68 for  vaccine  development  since  a  vaccine  working  against  one  species  might  not  protect 
 
69 against another (i.e. lack of cross reaction) (Feldmann & Geisbert 2011). A fifth member of 
 
70 the  Ebola  genus  (Reston  Ebola  virus,  REBOV) exists  in Asia;  however,  this  virus  is not 
 
71 thought to be lethal to humans, hence the EVD pathogenesis described below does not apply 
 
72 to this virus species. There have been no reported cases of EVD in orang-utans. 
 
73 The biological aspects of the EVD disease process are similar in humans and apes (Kuhn 
 
74 2008). EVs are highly infectious and enter the body through contact with mucus membranes, 
 
75 eyes,  and  broken  skin.  After  an  incubation  period  of  2-21  days,  the  infected  individual 
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76 develops symptoms which include fever, vomiting, diarrhoea, internal and sometimes external 
 
77 bleeding. There are few observations of wild apes that have presumably been suffering from 
 
78 EVD,  but  signs  of  abdominal  pain,  lethargy,  poor  appetite,  diarrhoea  and  emaciation  or 
 
79 simply “abnormal behaviour” have been noted in great apes, and bleeding from the nostrils 
 
80 has been observed among other non-human primates (NHPs) (Formenty et al. 1999, Georges 
 
81 et al. 1999, Lahm et al. 2007). Other individuals can get infected through contact with the 
 
82 body or body fluids from a sick or dead member of the social group (Warren & Williamson 
 
83 2004). It is debated how infection can spread through ape populations over large geographical 
 
84 areas and there are two main theories. The first theory proposes that the spread occurs solely 
 
85 by group-to-group infection after a single or few introductions of the virus from the original 
 
86 reservoir or other infected animals into an uninfected ape population. Such spread could occur 
 
87 via direct contact such as intergroup encounters, extra-community copulation, and emigration 
 
88 of females (including infected gorilla females leaving the group after death of the silverback), 
 
89 or indirectly, via sharing of feeding sites or home range (Vigilant et al. 2001, Bermejo 2004, 
 
90 Bradley et al. 2004). EV has been isolated in semen of infected human males many months 
 
91 after infection (Chughtai et al. 2016) indicating that surviving male apes could initiate new 
 
92 infection  chains if  mating occurs within the  infectious period.  The  potential for group-to- 
 
93 group spread in apes depends on several factors including the incubation time of the specific 
 
94 individual (or longevity of infectious semen), travel distance and ape density (Walsh et al. 
 
95 2007,   Walsh et al. 2009, Ryan et al. 2013). The sociality of African apes, including the 
 
96 natural  fission-fusion  social  system  of  chimpanzees  (Lehmann  &  Boesch  2004)  will  also 
 
97 influence the spread of virus in a positive or negative way, depending on the contact pattern 
 
98 and which individuals are infected. 
 
99 The second theory of how infection can spread over large areas proposes that outbreaks occur 
 
100 mainly as a direct consequence of repeated spill-over from a so far unidentified natural host 
 
101 into  geographically separated ape social  groups.  The  outbreak distribution is  consequently 
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defined by the dispersal and movements of the reservoir host itself rather than the apes (Leroy 
 
103 et al. 2004). However, these two theories are not mutually exclusive, as it is possible that both 
 
104 these modes of transmission are important, and that one or the other can predominate at times 
 
105 or sites depending on the underlying factors that trigger or sustain the outbreaks. In any case, 
 
106 Ebola’s tremendous ability to spread rapidly once it has emerged is illustrated by the recent 
 
107 human  outbreak  in  West  Africa,  which  started  with  one  infected  child  and  subsequently 
 
108 included nearly 30,000 people (Mari Saez et al. 2015, Anonymous 2015c). 
 
109 Experimental infections show that deaths in NHPs occur within a similar time frame as in 
 
110 humans (ca.8-10 days after onset of symptoms for ZEBOV and ca.12-14 days for TFEBOV) 
 
111 (Geisbert  et  al.  2009).  Although  the  mortality rate  can  be  extremely  high  (up  to  88%  in 
 
112 humans  and  possibly  higher  in  great  apes  infected  with  ZEBOV  [Bermejo  et  al.  2006, 
 
113 Anonymous  2015c]),  it  is  evident  that  recovery  and  survival  after  infection  is  possible. 
 
114 Antibodies to Ebola virus have been detected in blood from humans, wild-born chimpanzees 
 
115 and other primates and in the feces from wild-living gorillas, proving that some individuals 
 
116 exposed to the virus can mount an immune response and recover after infection  (Leroy et al. 
 
117 2004, Lahm et al. 2007, Reed et al. 2014). Survival of individuals in great ape groups whose 
 
118 other members have died of Ebola also suggest that recovery is possible (Formenty et al. 
 
119 1999, Bermejo et al. 2006); however, without laboratory testing of samples, it is not possible 
 
120 to ascertain whether these individuals were in fact infected or managed to escape exposure. 
 
121 The infectious, acute and often lethal nature of Ebola shows, however, that great apes are 
 
122 unlikely to be able to indefinitely sustain an infection chain. 
 
123 An  outbreak  stops  naturally  when  no  more  susceptible  individuals  come  in  contact  with 
 
124 infectious apes (dead or alive) or infectious materials. Leroy and colleagues (2004) reported 
 
125 carcasses remaining infectious in the rainforest for 3-4 days; it remains however uncertain 
 
126 
 
127 
how long EV survives under different environmental conditions (Anonymous 2014a). 
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OCCURENCE AND IMPACT OF EVD IN GREAT APES 
 
129 EVD  in  great  apes  was  first  recognized  nearly  twenty  years  after  the  Ebola  virus  was 
 
130 discovered  in  humans  (Pigott  et  al.  2014). Ape  outbreaks  have  mainly been  detected  in 
 
131 Central Africa whereas human outbreaks have occurred across tropical Africa (Figure 1). 
 
132 TFEBOV was the first ape-associated Ebola species to be discovered when 12 habituated 
 
133 chimpanzees  (Pan  troglodytes  verus)  in  the  Taї  National  Park,  Côte  d’Ivoire,  died  or 
 
134 disappeared  within  a  few  weeks  in  November  1994  (Formenty  et  al.  1999). Ebola  was 
 
135 confirmed by immunohistology staining of virus in carcass samples and by virus isolation 
 
136 from a researcher who contracted EVD after exposure to the carcass. Mortality rate in the 
 
137 chimpanzee group was estimated to ca. 25%, similar to what has been observed in outbreaks 
 
138 of human BEBOV (an Ebola species not detected in apes) (Towner et al. 2008). There was no 
 
139 further human-to-human transmission in this case and TFEBOV has not been detected again 
 
140 in Africa. 
 
141 The ZEBOV species has had a much more significant impact on great apes. Outbreaks have 
 
142 occurred in North Eastern Gabon and ROC in two clusters: first in the mid-1990s and then in 
 
143 the first five years of this century. Surveillance of wild great apes is challenging and does not 
 
144 cover  all  wild  populations  hence  outbreaks  could  also  have  occurred  undetected  at  other 
 
145 times. Most of what is known about the outbreaks in apes in North Eastern Gabon in the mid- 
 
146 1990s  emanated  from  investigations  of  three  human  outbreaks  that  occurred  at  that  time 
 
147 (Georges et al. 1999). In November 1994, there were concurrent reports of wildlife deaths 
 
148 among the local gorilla and chimpanzee populations when the first human cases appeared in 
 
149 gold  mining  camps  in  the  Minkebé  forest  area.  About  a  year  later,  butchering  a  dead 
 
150 chimpanzee  found  ca.  40  km  further  south  initiated  a  second  human  outbreak.  The  third 
 
151 human outbreak started yet another 160 km further south six months later with the death of 
 
152 two hunters, of which one was said to have killed several mangabeys in the time before he got 
 
153 sick. Dead chimpanzees and gorillas were encountered on several occasions during and after 
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these outbreak years, indicating that EVD was affecting the apes for a long time (Georges et 
 
155 al. 1999, Lahm et al. 2007). From these dead apes, a skin sample tested positive in Ebola 
 
156 immunohistology staining. 
 
157 Wildlife surveys carried out in Minkebé and Mwagne forest blocks before and after these 
 
158 outbreak  years  showed  a  dramatic  reduction  (90-98%)  in  the  gorilla  and  chimpanzee 
 
159 populations that could have been caused by a highly lethal, rapidly spreading disease like 
 
160 EVD (Huijbregts et al. 2003, Maisels et al. 2004, Lahm et al. 2007). In comparison, the 
 
161 mortality in humans exposed to the same virus was 59-75% in the concurrent outbreaks. The 
 
162 relatively lower human mortality is possibly due to hospital care of infected people rather than 
 
163 a higher biological disease resistance. 
 
164 A surveillance network was subsequently set up in North Eastern Gabon and ROC due to the 
 
165 association between human EVD outbreaks, the regularity of human contact with apes and/or 
 
166 ape meat in these countries and the decline of great ape populations. This network, which also 
 
167 included monitoring and sampling of a range of wildlife carcasses, revealed that five human 
 
168 EVD outbreaks that occurred between October 2001 and May 2005 resulted from contact to 
 
169 infected carcasses, mainly gorillas and chimpanzees (Leroy et al. 2004, Rouquet et al. 2005, 
 
170 Nkoghe et al. 2011). Ebola positive ape carcasses were found in several forest areas including 
 
171 Lossi  and  Odzala  National  Parks,  ROC,  where  population  losses  exceeding  90%  were 
 
172 observed in habituated gorillas (Bermejo et al. 2006). In Lossi alone Ebola was estimated to 
 
173 have killed 5,000 individuals.  Ebola is believed to have caused ape deaths in Odzala until at 
 
174 least 2007 (Caillaud et al. 2006, Cameron et al. 2016), however, since 2005, no further cases 
 
175 of EVD in African apes have been confirmed.  A human EVD outbreak in Boende, DRC, in 
 
176 2014  might  have  been  linked  to  contact  with  a  primate  carcass  (species  unidentified) 
 
177 (Maganga  et  al.  2014),  however,  no samples have been obtained  for testing and the link 
 
178 remains speculative. The human 2013-2016 EVD epidemic in West Africa is not believed to 
 
179 be associated with deaths of great apes or other primates, but is rather thought to be the 
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consequence of a child’s accidental contact with a large colony of insectivorous bats (Mari 
 
181 Saez et al. 2014). The area where the epidemic started harbours few primates, no case of dead 
 
182 apes  has  been  reported  and  recent  surveys  indicate  no  decline  in  primate  populations 
 
183 compared with surveys conducted prior to the outbreak. 
 
184 In  summary,  EVD  has  likely killed  thousands  of  gorillas  and  chimpanzees  in  the  central 
 
185 African rainforests where the majority of the world’s remaining great ape populations reside 
 
186 (Vogel  2006,  Hopkin  2007). Because  of  these  losses,  the  IUCN  upgraded  the  western 
 
187 lowland gorilla to critically endangered in 2007 (Walsh et al. 2007). Carcass samples and 
 
188 precise assessments of wild great ape population sizes are challenging to obtain, making it 
 
189 difficult to estimate the true impact of Ebola on great apes. There is, however, no reason to 
 
190 doubt that EVD can severely affect great ape populations; and in fact, until the start of the 
 
191 recent epidemic in West Africa, the number of apes estimated to have succumbed to Ebola 
 
192 was far greater than the total number of people (ca.1500) who died from the same virus in all 
 
193 
 
194 
known human outbreaks (Anonymous 2015b). 
 
195 WHERE AND HOW DO THE APES GET INFECTED WITH EBOLA? 
 
196 It  is  evident  from  the  disease’s  rapid  spread  and  high  mortality  in  great  apes  that  these 
 
197 primates  are  neither  natural,  asymptomatic  carriers  of  the  virus  nor  able  to  sustain  the 
 
198 infection indefinitely, which are both important criteria for a reservoir host (Olival & Hayman 
 
199 2014). The apes are rather so-called ‘accidental hosts’ who act as a source of infection for 
 
200 human outbreaks when they themselves are infected from another host(s) sharing the same 
 
201 habitat. Numerous carcasses of other animals found in the Gabon and ROC forests between 
 
202 1994 and 2005 indicate that many species may be susceptible to EV, although the virus has 
 
203 only  been  isolated  from  gorillas,  chimpanzees  and  a  duiker  (Cephalophus  sp.)  despite 
 
204 intensive testing of wildlife carcasses in outbreak areas for decades (Leroy et al. 2004, Lahm 
 
205 et al. 2007, Wittmann et al. 2007). Laboratory analyses of samples from certain fruit eating 
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and insect eating bats indicate that these bats were able to host, possibly spread and indeed 
 
207 survive infection; however, the virus itself has never been isolated from these hosts and more 
 
208 research is necessary to confirm that the virus is circulating primarily in any of these species 
 
209 or if yet another host represents the true reservoir (Olival & Hayman 2014, Leendertz et al. 
 
210 2015).    Until the natural history and ecology of Ebola are more fully characterized, it is only 
 
211 possible to speculate about if and how apes (and humans) get infected from bats or other 
 
212 species (Viana et al. 2014). Apes are not known to hunt bats, but could potentially come in 
 
213 direct contact with fruit bats roosting in trees where apes feed, or with insectivorous bats 
 
214 roosting  in  tree  holes  where  the  apes  search  for  honey,  insects  or  water  (Nishida  2010). 
 
215 Alternatively they could get infected via excretions from any kind of bat or other animal when 
 
216 ingesting  contaminated  food  via  feces,  urine  or  saliva,  although  such  excretion  of  EV  in 
 
217 naturally infected bats is yet to be confirmed (Olival & Hayman 2014). Direct contact with 
 
218 other infected hosts is another possible infection route, including hunting of monkeys or other 
 
219 prey that might be infected and/or during inspections of infected carcasses (Boesch & Boesch- 
 
220 Achermann 2000, Karesh et al. 2012). In the chimpanzee outbreak in Côte d’Ivoire, red 
 
221 colobus monkey predation was considered a risk factor (Formenty et al. 1999), but was not 
 
222 confirmed as a transmission route. 
 
223 The uncertainties of Ebola ecology make predicting outbreaks in wildlife (and humans when 
 
224 no previous wildlife outbreak is detected) nearly impossible and without further data most of 
 
225 the tropical belt of Africa is considered a risk area for Ebola emergence (Pigott et al. 2014). 
 
226 This has implications for outbreak preparedness in humans and wildlife alike. What is clear, 
 
227 however, is that apes are intermittently exposed to EVs in their natural environment, which 
 
228 means that we might not be able to remove, or prevent exposure to, the source of infection. 
 
229 This highlights the need for considering strategies to prevent  EV infection  of great apes, and 
 
230 to also break the link between them and human EVD outbreaks (Feldmann & Geisbert 2011). 
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232 
 
THE BENEFITS AND POSSIBILITIES OF PREVENTING OR REDUCING SPREAD 
 
233 OF EBOLA WITHIN APE POPULATIONS 
 
234 Considering  the  severe  reduction  in  population  number  and  dissemination  of  groups  that 
 
235 follows EVD outbreaks in great apes it is highly questionable if leaving this disease to be 
 
236 regulated  by nature  itself is a  viable  option. Demographic  structure changes (for example 
 
237 increased frequency of emigration to start new breeding groups) of populations after severe 
 
238 declines can indeed occur to favour population growth (Genton et al. 2012, Genton et al. 
 
239 2014, Reed et al. 2014), however, in the case of repeated outbreaks and added pressure from 
 
240 other infectious diseases, bushmeat hunting and deforestation these recovery strategies might 
 
241 not be sufficient to prevent extinction (Leendertz et al. 2006, Morgan & Sanz 2007, Kondgen 
 
242 et al. 2008, N'Goran et al. 2012).   Apes have a relatively long generation time (Anonymous 
 
243 2014a) which means that an outbreak of a disease with high mortality rate such as EVD 
 
244 requires a very long recovery time for affected populations; some calculated that it would take 
 
245 the affected gorilla population in Lossi more than 130 years to recover to initial population 
 
246 numbers (Ryan & Walsh 2011). In addition, fragmentation of populations due to mortality 
 
247 also has a negative impact on the genetic diversity of the populations, which could exacerbate 
 
248 extinction risk especially when populations  are reduced in size.  Therefore,  it is clear that 
 
249 efficient strategies to reduce the impact on EVD in wild population will be beneficial for 
 
250 conservation.  Further,  prevention  or  reduction  of  infectious  diseases  in  wildlife,  including 
 
251 preservation of natural ecosystem integrity and biodiversity, will ultimately have a positive 
 
252 impact on human health (Rabinowitz et al. 2013).   It should however be noted that not all 
 
253 human EVD originated from infected great apes, hence such strategies will not prevent human 
 
254 exposure to EVs from other wildlife sources (Anonymous 2015a). 
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The questions that arise when any wildlife is concerned, is if any intervention in a natural 
 
256 ecosystem is justified.  The benefits of any intervention must be assessed in conjunction with 
 
257 the  potential  negative  impacts  (Fedigan  2010,  Gruen  et  al.  2013).  Nearly  all  great  ape 
 
258 populations have been, and continue to be, impacted by human influence, such that apart from 
 
259 some of the protected areas, the majority of the African forests can no longer be considered 
 
260 ‘natural’ (Laurance 2009, Hockings et al. 2015).  Preserving protected species is required by 
 
261 law and there should be an additional moral responsibility to preserve endangered species, 
 
262 and  further,  human-induced environmental  changes  such  as  deforestation  and  urbanisation 
 
263 may exacerbate the likelihood of EV emergence (Waldman 2015). Hence it seems rational to 
 
264 focus upon how to protect the remaining wild great apes from a disease that are incompatible 
 
265 with survival of  the  species  should outbreaks  continue  to occur,  rather than discussing if 
 
266 human  intervention  is  justified.  Hypothetical  possibilities  to  prevent  the  spread  of  Ebola 
 
267 within ape populations exist, however the questions of which strategy or strategies would be 
 
268 feasible and efficient, despite limited knowledge about the natural ecology of these viruses 
 
269 and their unpredictable emergence, remains. 
 
270 In human EVD outbreaks, isolation of infected cases remains an important control strategy 
 
271 (Anonymous 2015d). Protection of the great apes cannot rely upon similar isolation strategies, 
 
272 although it might naturally occur to some degree as apes sometimes temporarily leave the rest 
 
273 of the social group when experiencing signs of disease (Boesch & Boesch-Achermann 2000). 
 
274 It is evident that some isolated groups of chimpanzees and gorillas continued to thrive in one 
 
275 instance only 20km from an outbreak area (Lahm et al. 2007), hence geographical separation 
 
276 could theoretically provide protection. However, attempting to isolate social groups by cutting 
 
277 corridors in the forest in order to stop spread  of infected apes is unlikely to be  feasible, 
 
278 desirable  or  efficient  for  various  reasons.  Firstly,  clearing  of  larger  geographical  areas  in 
 
279 dense and remote rainforest areas is laboursome and in conflict with forest preservation, and 
 
280 as apes are able to cross large open areas the effort might not even be worthwhile (Haurez et 
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al. 2013). Further, should separation be successful it might create stress for the apes due to 
 
282 man-made  disturbance  and  change  in  their  territory,  and  in  longer  term  compromise  the 
 
283 population genetic viability. And finally, the virus could be introduced to other parts of the 
 
284 forest  by  reservoir  hosts  not  restricted  by  human-made  barriers,  which  make  attempts  to 
 
285 geographically separate ape groups to avoid spread of infection redundant. 
 
 
286 
 
Preliminary  results  regarding  experimental  post-exposure  treatments  based  on  protective 
 
287 antibodies (e.g. ZMapp) are encouraging; however, patients require additional intensive care, 
 
288 hence such medication is unlikely to be effective in controlling EVD outbreaks in wild apes, 
 
289 even  when  habituated.  Vaccination,  i.e.  administration  of  preventative  medication  which 
 
290 stimulates an immune response that will protect the individuals against natural exposure to the 
 
291 virus,  could  possibly  be  the  most  promising  control  strategy  in  great  apes.  Indeed,  the 
 
292 prospect of safe and efficient Ebola vaccines in the near future invites a discussion about their 
 
293 use in wild populations of great apes (Marzi & Feldmann 2014). There are significant ethical 
 
294 issues when considering the vaccination of wild great apes, though it should be noted that in 
 
295 humans  the  prospective  use  of  vaccines  is  also  not  without  its  own  ethical  and  practical 
 
296 concerns (Cohen & Kupferschmidt 2014, Lee et al. 2015). 
 
 
297 
 
It is not the first time that vaccines have been used in wild apes (Ryan & Walsh 2011). For 
 
298 example, small scale vaccination has been done in habituated (or reintroduced) populations 
 
299 for diseases like measles, poliomyelitis, tetanus, and anthrax (Goodall 1986, Hastings et al. 
 
300 1991, Ryan & Walsh 2011).   Vaccinations were done through distance darting,  injections 
 
301 when  other  interventions  were  undertaken  under  general  anaesthesia,  or  in  the  case  of 
 
302 chimpanzee  poliomyelitis  in  the  mid-1960s,  through  feeding  of  bananas;  an  acceptable 
 
303 
 
 
304 
practice at the time. 
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THE PROSPECT OF VACCINATING WILD GREAT APES AGAINST EBOLA 
 
306 Implementation of great ape vaccination programs seems superficially straightforward, since 
 
307 humans  and  great  apes  are  genetically  and  physiologically  similar  and  exhibit  similar 
 
308 immunological reactions to vaccines. However, accessibility of great apes due to their elusive 
 
309 nature and occurrence in remote habitats, limits the choice of vaccine(s) and call for well- 
 
310 considered vaccination strategies. A thorough understanding of EVD, the great apes natural 
 
311 behavior, and the vaccines that might become available in the future is required for discussing 
 
312 
 
 
313 
and deciding on appropriate vaccination strategies. 
 
 
314 
 
CURRENT VACCINE CANDIDATES 
 
315 In the last decades, a number of vaccine types have been tested in suitable animal models 
 
316 including  non-human  primates  and  some  have  subsequently  advanced  into  human  clinical 
 
317 trials (Marzi & Feldmann 2014, Falzarano 2016).   Regardless if a vaccine is intended for 
 
318 human or great ape use, it is extremely important to assure its safety; crisis situations should 
 
319 not bypass the need to establish a vaccine’s risk-benefit profile and to address both real and 
 
320 perceived safety concerns (Lee et al. 2015, Rougeron et al. 2015). 
 
321 To understand the possible use and limitations of vaccines in great apes (and humans), it is 
 
322 essential to understand that vaccine candidates differ in their composition; defining so-called 
 
323 different  vaccine  platforms  (Marzi  &  Feldmann  2014). The  composition  of  the  vaccine 
 
324 determines which type and degree of immune reaction it stimulates, and if a vaccine needs to 
 
325 be  injected  rather  than  administered  via  other  routes  to  induce  sufficient  protection  from 
 
326 infection. Subsequently, this decides which type and how many interventions are necessary on 
 
327 the individual or population level to induce protection and how long this protection lasts. 
 
328 Several  Ebola  vaccine  candidates  are  vector-based  vaccines  that  consist  of  some  type  of 
 
329 relatively benign virus that has been genetically modified to display Ebola specific antigens 
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on the surface. In this way, the vector virus will present itself as Ebola virus to the vaccinated 
 
331 host  and  activate  an  appropriate  immune  response  as  long  as  it  is  viable.  Such  vaccine 
 
332 candidates include cAd3-EBO-Z and rVSV-ZEBOV which have both proven to be protective 
 
333 after one single injection in NHP-studies and are currently in human trials (Henao-Restrepo et 
 
334 al. 2015, De Santis et al. 2016). rVSV-ZEBOV can also be used when the individual is already 
 
335 infected with Ebola, and an important feature which might be relevant for the possible use in 
 
336 wild apes is that oral immunization with this vaccine has proven possible, at least in the 
 
337 mouse and macaque model,  suggesting that baiting of vaccine is in theory possible (Qiu et al. 
 
338 2009). 
 
339 Another  type  of  vector based  vaccine  candidate is  Cytomegalovirus  based  vaccine  (CMV 
 
340 vaccine)  (Marzi  et  al.  2016).  In contrast to the other candidates, this vaccine  is intended 
 
341 specifically for wild great apes and is designed to be able to spread from one individual to 
 
342 another.  Ideally  the  vaccine  virus  should  be  given  to  relatively  few  individuals  and 
 
343 subsequently spread through the population indefinitely whilst stimulating protection against 
 
344 Ebola. However, the ethics and risks of introducing any genetically modified virus, even if the 
 
345 original  vector  virus  is  naturally  found  in  the  population,  requires  careful  and  thorough 
 
346 discussion (Tsuda et al. 2011, Murthy et al. 2013). Once released, the vaccine-virus can no 
 
347 longer be removed from the population. 
 
348 A vaccine with less safety concerns is Virus Like Particles-vaccine; it does not include any 
 
349 virus component but rather consists of a genetically engineered protein product that mimics 
 
350 the   structure   of   EV   (Marzi   &  Feldmann  2014).   Studies  in  NHP,   including  captive 
 
351 chimpanzees, show that multiple injections are required to reach full potency of the vaccine, 
 
352 hence there are doubts about the use of this vaccine in the wild (Warfield et al. 2014). 
 
353 Additional candidates have also proven protective in NHP models and vaccine research is 
 
354 currently progressing rapidly hence further candidates and possibly additional administration 
 
355 routes are likely to appear in the future (Bukreyev & Collins 2010, Geisbert 2015). 
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357 POSSIBLE VACCINATION STRATEGIES 
 
358 The different properties of the vaccines determine how they can be administered, how many 
 
359 individuals might be protected after a single intervention and how long protection lasts. The 
 
360 selection of vaccine and cost-effective vaccination strategy are therefore mainly determined 
 
361 by 1) the access to the apes, i.e. if they are habituated to human presence or not, and 2) the 
 
362 aim of vaccination at the time, i.e. to prevent introduction of Ebola from the natural source 
 
363 into the ape population or to stop the spread of infection within populations once an outbreak 
 
364 has  started.  Wild  apes  that  have  been  habituated  for  behavioral  research  or  tourism  are 
 
365 observed on a regular basis and individual apes are usually identified which means that initial 
 
366 vaccination, monitoring and possible follow-up vaccination are in theory possible, whereas 
 
367 unhabituated apes would not be accessible for such treatment. The majority of apes in Africa 
 
368 are  not  habituated  although  for  some  relatively  small  populations  such  as  the  Virunga 
 
369 Mountain Gorillas, a relatively large proportion (ca.70%) is habituated (Robbins et al. 2011). 
 
370 It should, however, be noted that these apes, including sanctuary apes (Anonymous 2016b), 
 
371 are wild and endangered although they are habituated, and should therefore not be considered 
 
372 guinea pigs for experimental vaccinations. For unhabituated apes, their population size and 
 
373 location, and even existence, might not be known, hence access to these apes and monitoring 
 
374 of vaccination coverage is a real challenge. 
 
375 For these reasons it is possible that different vaccines and strategies are suitable according to 
 
376 the  specific  population  in  question. Strategies  will  be  discussed  below  in  general  terms 
 
377 without referring to current candidates as additional candidates will likely become available 
 
378 
 
379 
(Figure 2). 
 
380 Prevention of Ebola spill-over into habituated populations 
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The more or less constant proximity of habituated apes makes darting a possible route of 
 
382 vaccine administration. Although it can be challenging and possibly dangerous to the apes and 
 
383 personnel, darting yields a high degree of certainty that the vaccine has been received. Ideally 
 
384 a vaccine that protects after a single administration should be used to avoid excessive darting 
 
385 that might also have a negative impact on years or decades of habituation efforts. For the 
 
386 same  reason  the  vaccine  (with  or  without  required  booster)  should  induce  long  lasting 
 
387 protection. Although the vaccine candidates that are presently in human trials are considered 
 
388 to  induce  long-term  protection  sufficient  to  last  for  the  duration  of  a  human  outbreak,  a 
 
389 protection longevity of some months or even a couple of years  might not be optimal for long 
 
390 term prevention of EVD in wild apes (Stanley et al. 2014, Wong et al. 2014). 
 
391 Baiting  is  in  theory  another  option  for  vaccine  delivery  to  habituated  apes,  provided  the 
 
392 vaccine is designed to induce protection after oral administration. However, apes are selective 
 
393 with what they eat hence it might be difficult to ensure that all individuals receive the vaccine 
 
394 or on the other hand that a single or few dominant individuals consume vaccine doses higher 
 
395 than intended (Ryan & Walsh 2011). Furthermore, feeding wild great apes with food items 
 
396 that might be desirable but foreign to them, e.g. bananas, is not a generally accepted practice; 
 
397 however,  the  cost-benefit  of  such  provisioning  for  vaccination  purpose  might  have  to  be 
 
398 reconsidered. 
 
399 As the number of habituated great apes is relatively small, it could be possible to vaccinate all 
 
400 or at least the majority of them (figure 2b), provided the costs are covered. If not, specific 
 
401 members that are important for reasons such as breeding potential and/or disease spreading 
 
402 capabilities within the social network must be selected according to the specific species and 
 
403 demographic structure for the population in question (Carne et al. 2013). It should, however, 
 
404 be  kept  in  mind  that  as  long  as  the  ecology and  transmission  of  Ebola  from  the  natural 
 
405 reservoir is not determined, high-risk individuals within a group cannot be identified. If a safe, 
 
406 efficient and ethically accepted self-spreading vaccine  should become available  for  use in 
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great  apes  (as  suggested  by  Marzi  and  collegues  (2016)),  such  selection  would  not  be 
 
408 necessary  and  relatively  few  individuals  would  require  darting  to  induce  high  level  of 
 
409 
 
410 
vaccination cover and longevity of protection in a population (figure 2d). 
 
411 Control of EVD outbreaks in habituated populations 
 
412 Trying to vaccinate by darting during a great ape Ebola outbreak is likely to be stressful and 
 
413 dangerous for human personnel and apes. Human safety must be addressed in planning of any 
 
414 intervention whether the ape population is habituated or not. Further, the rapid progression of 
 
415 disease and death leaves little time to vaccinate which makes it more essential to follow a 
 
416 logistically feasible vaccination priority list to prevent further spread of infection.   A ‘ring 
 
417 vaccination’ (figure 2c) of in-contact individuals and individuals in surrounding unaffected 
 
418 populations could be attempted (Henao-Restrepo et al. 2015). This approach might, however, 
 
419 not  be  fast  or  efficient  enough  to  stop  the  outbreak,  and  virus  could  also  possibly  be 
 
420 introduced directly from the reservoir on the other side of the vaccination-borders (Leroy et 
 
421 al. 2004). In an outbreak situation, it would be beneficial to use a vaccine that is effective also 
 
422 when an individual is already infected. Protection induced by a potential self-spreading type 
 
423 of vaccine would require that the vaccine vector would spread and induce protection faster 
 
424 than the Ebola virus itself would spread; such a vaccine would make more sense to use well 
 
425 before an outbreak situation but could perhaps be beneficial if used in parallel with other 
 
426 vaccinations as an extension of a ring vaccination strategy. 
 
427 An important issue is that a great ape outbreak might be accompanied by human cases. If 
 
428 there is low availability of vaccines developed for human use, one should seriously consider 
 
429 
 
430 
the cost-benefit and ethics of using these valuable doses on wildlife. 
 
431 Prevention of Ebola spill-over into non-habituated populations 
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The  elusive  nature  of  non-habituated  apes  poses  a  considerable  obstacle  to  administering 
 
433 injectable  vaccines  and it  is  questionable  if  vaccinating  randomly  encountered  individuals 
 
434 would be sufficient to protect populations across Africa, especially if the vaccination would 
 
435 require  booster  injections  after  some  time.  The  cost-benefit  must  be  modelled  for  the 
 
436 individual populations, including factors such as to what proportion of the population can be 
 
437 expected  to  be  reached,  and  the  perceived  risk  of  viral  spill-over  in  the  area.  The 
 
438 unpredictable emergence of Ebola from its reservoir makes such risks difficult to estimate. 
 
439 Although  relatively  specific  areas  in  North  Eastern  Gabon,  ROC  and  Cote  d’Ivoire  have 
 
440 proven to be ecologically suitable for transmission of Ebola into great ape population, the 
 
441 majority of the tropical belt of Africa is currently considered risk area for viral emergence 
 
442 (Pigott et al. 2014, Walsh & Haseeb 2015). 
 
443 Baiting does not require close-range contact with individuals, but poses the same challenges 
 
444 as described for habituated apes and also requires efficient administration on a much larger 
 
445 geographical scale. A self-spreading vaccine that would require relatively few interventions 
 
446 and which could in theory provide widespread protection against Ebola may seem promising 
 
447 for remote, non-accessible populations but the safety and ethics of such an approach must be 
 
448 addressed. 
 
449 Other ideas would be to develop efficient fog sprays or environmental vaccines that can be 
 
450 administered  to  larger  areas  of  remote  ape  habitats,  or  when  the  Ebola  ecology  is  better 
 
451 
 
452 
understood, to vaccinate species that the apes could contract Ebola infection from. 
 
453 Control of EVD outbreaks in non-habituated populations 
 
454 Firstly,  outbreaks  in  un-monitored  populations  are  likely  to  go  unnoticed  or  to  be  first 
 
455 recognized when it is large enough  to be detected by wildlife surveys, unless there is an 
 
456 efficient hunter surveillance network already in place. Secondly, for reasons discussed above, 
 
457 reaching  and  vaccinating  enough  unhabituated  individuals  in  order  to  control  a  rapidly 
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spreading outbreak is unlikely. Ring vaccination of unaffected habituated groups might be 
 
459 considered  to  prevent  spread  of  infection  to  groups  outside  of  the  ring,  or  to  protect 
 
460 
 
461 
particularly vulnerable groups within the ring. 
 
462 SUMMARY OF FEASABILITY AND CHALLENGES OF EFFICIENT 
 
463 VACCINATION OF WILD APES 
 
464 There are currently a number of challenges to be overcome before vaccination can be efficient 
 
465 from a conservation perspective. Nevertheless, strategies should be formulated and discussed 
 
466 based on up-to-date knowledge and the prospects of future advances in vaccine development, 
 
467 to prepare financially and logistically for possibly rapid changes in vaccine availability. This 
 
468 needs to be  done  for each specific population  to accommodate for differences in species, 
 
469 population size, habituation status, accessibility and other factors relevant to the countries in 
 
470 question.  Management  plans  can  be  discussed  and  adjusted  according  to  changes  in  the 
 
471 development,  availability  and  cost  of  vaccines,  disease  situation,  knowledge  about  Ebola 
 
472 ecology,  and  opinion  on  wildlife  vaccination.  To  this  end,   interdisciplinary  meetings 
 
473 including  representatives  from  the  fields  of  primatology,  virology,  wildlife  conservation, 
 
474 ecology, epidemiology, virology, immunology and public health are necessary to discuss and 
 
475 find well-considered solutions for this complex topic. These discussions should also include 
 
476 how to record details of any vaccination attempt and how to monitor the effect in a scientific 
 
477 way (Travis  et  al.  2008).  The  more  data  that are  available,  the better we  can  implement 
 
478 
 
479 
disease models and adjust future disease prevention strategies. 
 
480 NEED  FOR  GREAT  APE  HEALTH  MONITORING,  RESEARCH  AND  DISEASE 
 
481 AWARENESS 
 
482 Irrespective if future strategies for preventing Ebola will be implemented or not, monitoring 
 
483 of great ape health itself is important and should be included into conservation plans together 
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with poaching control and habitat protection (Travis et al. 2006). Further, the fact that apes 
 
485 and humans alike are highly susceptible to Ebola make the great apes important sentinels for 
 
486 human disease, therefore monitoring mortality in these wildlife hosts, and collecting samples 
 
487 for pathogen identification, remains an important corner stone to predict and possibly prevent 
 
488 zoonotic transmission into humans (Calvignac-Spencer et al. 2012). It is the responsibility of 
 
489 any conservation and research project to take wildlife death seriously, to develop protocols in 
 
490 the event of a disease outbreak and report cases even if the project itself is not engaged in 
 
491 great ape health. This should go hand in hand with raising public awareness about the risk of 
 
492 hunting  and  scavenging  apes,  and  also  highlighting  the  importance  of  hunters  and  other 
 
493 villagers  reporting  dead  apes,  perhaps  via  the  chiefs  of  the  villages  to  the  local  health 
 
494 authorities.  During  the  first  bout  of  human  outbreaks  in  Gabon  in  the  nineties,  lack  of 
 
495 awareness  of  the  role  of  great  apes  in  Ebola  outbreaks  limited  the  epidemiological  and 
 
496 laboratory investigation of these species. The need for wildlife monitoring was subsequently 
 
497 recognized  and  in  the  next  series  of  outbreaks  some  years  later  a  well prepared  wildlife 
 
498 monitoring network was able to warn the health authorities about the risk of human cases and 
 
499 sampling of carcasses lead to the confirmation of   infected apes and duikers as root of the 
 
500 human outbreaks (Rouquet et al. 2005). 
 
501 Great ape monitoring should be done in a systematic and quantitative manner by qualified 
 
502 personnel, such as veterinarians  that have been trained to perform wild animal necropsies 
 
503 under highly stringent safety conditions. Such monitoring has been shown to be a prerequisite 
 
504 for early detection and effective sampling of suspected cases (Leendertz et al. 2006, Travis et 
 
505 al. 2008); laboratory analysis is the only way to confirm Ebola infection. Antibody testing of 
 
506 non-invasively collected great ape samples can show which population have been exposed to 
 
507 the virus and surveys to estimate group density and population numbers may inform about 
 
508 population declines possibly caused by Ebola (Cameron et al. 2016, Campbell et al. 2008, 
 
509 Kouakou et al. 2009, Olson et al. 2012, Reed et al. 2014). Identification of the virus’ true 
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reservoir and infection pathways in nature remains important research (Leendertz 2016).  This 
 
511 emphasizes the need for continuous funding and recruitment of people involved with disease 
 
512 monitoring, ranging from veterinarians to field primatologists, project managers, ecologists, 
 
513 and  laboratory workers.  We  encourage  the  involvement  of  researchers  and laboratories  in 
 
514 great ape countries for increased sustainability of such work. 
 
515 Although not all human EVD outbreaks that have occurred can be linked to deaths in great 
 
516 apes, it is clear that contact with bush meat from any species of great ape either via hunting, 
 
517 scavenging or butchering, is a major risk factor for exposure to Ebola virus (Feldmann & 
 
518 Geisbert   2011,   Anonymous   2014c). This   epidemiologically   and   laboratory-confirmed 
 
519 transmission pathway should be a reminder that hunting animals that may be infected with EV 
 
520 can  increase  the  risk  of  human  outbreaks.  Continuous  public  education  by  health  and 
 
521 conservation organizations in great ape countries remains an important and priority task for 
 
522 disease prevention; a good example is the hunter surveillance and public health programme in 
 
523 Northern Congo (Anonymous 2015e).   Such outreach programmes that communicate, in a 
 
524 culturally sensitive way, the dangers of handling bushmeat enhance awareness of zoonotic 
 
525 infections from great apes and other wildlife. Although it would not affect the occurrence of 
 
526 EVD  in  apes,  there  may  be  indirect  benefits  to  conservation.  Possible  risks  of  disease 
 
527 transmission between apes and humans must also be conveyed to tourists that are in relatively 
 
528 close  contact  with  wild  great  apes  in  tourism-for-conservation-  projects  (Muehlenbein  & 
 
529 
 
530 
Ancrenaz 2009, Macfie & Williamson 2010). 
 
531 WHAT TO DO IF EBOLA IS SUSPECTED OR CONFIRMED IN APES? 
 
532 This review is not meant as a manual for collection and analyses of data and samples; for this 
 
533 we refer to other guidelines for great ape health monitoring (Gilardi et al. 2015). First and 
 
534 most important is to never forget that the Ebola virus is highly infectious and highly lethal and 
 
535 represents a major risk to human health; well-meaning, unskilled or unprotected investigators 
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or  tourists  as  well  as  highly-trained  public  health  workers  might  risk  their  own  life  and 
 
537 possibly initiate a human outbreak. The rapid decomposition of carcasses in the rainforest 
 
538 means that finding a single carcass is very rare, hence encountering even one dead ape should 
 
539 raise awareness as this individual might be one of many other undetected carcasses and an 
 
540 immediate  and  intense  search  should  be  initiated.  Whenever  an  ape  carcass  is  detected, 
 
541 especially if Ebola is suspected, the wildlife authorities and the local ministry of health should 
 
542 be informed, following the ROC surveillance guidelines (Reed et al. 2014). Necropsy samples 
 
543 should only be sampled by specialists trained for these situations, and anybody in direct or 
 
544 indirect contact with carcasses must adhere to the highest standard of protective clothing and 
 
545 disinfection (Leendertz et al. 2006, Ringen et al. 2015). 
 
546 The possibility and limitations of vaccination in an outbreak situation, as described above, 
 
547 should ideally have been discussed well beforehand and a  network of assistance for such 
 
548 emergency  situations  should  be  established.  Finally,  openly  sharing  experiences  after  an 
 
549 
 
550 
outbreak is crucial for improving preparedness for future outbreaks. 
 
551 CONCLUSION 
 
552 Ebola Viruses can cause large epidemics in humans and great apes. The likelihood that these 
 
553 viruses will continue to emerge unpredictably in tropical Africa highlights the necessity to 
 
554 protect apes from the severe impact of EVD and to reduce human contact to infected wildlife 
 
555 sources.  Further  research  is  required  to  determine  the  natural  circulation  of  EVs  and  the 
 
556 mechanisms facilitating viral emergence; however, bushmeat from infected apes is confirmed 
 
557 as source of infection for human outbreaks hence public education of zoonotic diseases and 
 
558 monitoring of great ape health remain important human outbreak prevention strategies. With 
 
559 the  rapid  progress  in  Ebola  vaccine  development,  vaccination  of  wild  great  apes  might 
 
560 become a tool for conservation and protection of human health in the future. Research must 
 
561 focus on developing safe and efficient safe vaccines that can be delivered efficiently to larger 
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populations of elusive wild apes in their natural remote habitats.  A thorough understanding of 
 
563 the disease and the great apes’ natural behavior as well as knowledge of the properties of 
 
564 vaccine candidates is necessary to assess the feasibility of potential vaccination programs. 
 
565 This article describes the occurrence of EVD in great apes and discusses the possibilities and 
 
566 
 
 
567 
limitations of vaccinating wild great apes against Ebola. 
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FIGURE LEGENDS 
 
 
Figure 1. Overview of Ebola-positive great ape carcasses and points of origin of human 
outbreaks across the tropical belt of Africa. The larger green areas in Gabon and ROC 
represent the three and five outbreaks, respectively (Pigott et al. 2014, Anonymous 2015c) 
 
Figure  2.  Schematic  presentation  of  the  principles  of  Ebola  vaccination  strategies  in 
 
926 great apes 
 
927 A- vaccination border for prevention of spillover from natural reservoir or other hosts; B- 
 
928 vaccination of specific groups, i.e. habituated groups; C-ring vaccination in the event of an 
 
929 EVD outbreak; D- the principle of a self-spreading vaccine. The bats represent any possible 
 
930 source  of  Ebola  infection.  The  open  dots  and  circles  on  the  grey  background  illustrate 
 
931 individuals and groups in the ape population. Black dots are Ebola infected apes; red dots are 
 
932 vaccinated apes. 
 
933 Red  arrows  indicate  introduction  of  vector  virus,  the  orange  dots  and  arrows  shows 
 
934 
 
935 
subsequent spread, white arrows indicate route of even further spread. 
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